Century Therapeutics Inc
Century Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19… Read more
Century Therapeutics Inc (IPSC) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.145x
Based on the latest financial reports, Century Therapeutics Inc (IPSC) has a cash flow conversion efficiency ratio of -0.145x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-25.58 Million) by net assets ($176.35 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Century Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how Century Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Century Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Century Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
INTERGRATED DIA.H DL 025
F:8I8
|
N/A |
|
Dongnan Electronics Co. Ltd. A
SHE:301359
|
N/A |
|
RF Industries Ltd
NASDAQ:RFIL
|
0.060x |
|
Shaanxi Meibang Pharmaceutical Group Co Ltd
SHG:605033
|
0.246x |
|
AM Locales Property Socimi
MC:YAML
|
0.112x |
|
American Oncology Network Inc.
NASDAQ:AONC
|
0.110x |
|
Shinsegae Inte
KO:031430
|
-0.046x |
|
Share India Securities Limited
NSE:SHAREINDIA
|
-0.081x |
Annual Cash Flow Conversion Efficiency for Century Therapeutics Inc (2015–2024)
The table below shows the annual cash flow conversion efficiency of Century Therapeutics Inc from 2015 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $161.36 Million | $-110.14 Million | -0.683x | -42.73% |
| 2023-12-31 | $184.75 Million | $-88.35 Million | -0.478x | -1130.25% |
| 2022-12-31 | $302.74 Million | $14.05 Million | 0.046x | +120.66% |
| 2021-12-31 | $396.24 Million | $-89.00 Million | -0.225x | -157.92% |
| 2020-12-31 | $-106.41 Million | $-41.27 Million | 0.388x | +120.34% |
| 2019-12-31 | $-91.86 Million | $-16.17 Million | 0.176x | -39.30% |
| 2015-12-31 | $359.71 Million | $104.30 Million | 0.290x | -- |